Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Number of trips per Whoosh user increased 32%

6/21/24 WUSH

Shareholders of Sberbank approved dividends for 2023

6/21/24 SBER

Yandex Go launched electric bicycle rental in Moscow

6/21/24 YDEX

China's Wison is leaving Russia

6/21/24 NVTK

Government determined the amount of Transneft dividends

6/21/24 TRNFP

Shareholders of Rosseti Centere approved dividends for 2023

6/20/24 MRKC

Moscow Exchange postpones the first pre-IPO transaction

6/20/24 MOEX

Moscow Exchange postpones the first pre-IPO transaction

6/20/24 OTCI

VK to launch VK Tutoria tutoring service

6/20/24 VKCO

Shareholders of Rosseti Volga approved dividends for 2023

6/20/24 MRKV